In a report released on April 12, David Low from J.P. Morgan maintained a Hold rating on Nanosonics Limited (NNCSF – Research Report), with a price target of A$4.40. The company’s shares closed last Thursday at $3.25.
Low covers the Healthcare sector, focusing on stocks such as Resmed, Nanosonics Limited, and Ramsay Health Care. According to TipRanks, Low has an average return of 0.8% and a 51.02% success rate on recommended stocks.
Currently, the analyst consensus on Nanosonics Limited is a Moderate Sell with an average price target of $3.00.
See today’s best-performing stocks on TipRanks >>
Based on Nanosonics Limited’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $0. In comparison, last year the company had a net profit of $0
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nanosonics Ltd is an Australia based healthcare equipment manufacturing company. It manufactures and distributes the trophon EPR ultrasound probe disinfector, which reduces the risk of ultrasound-related cross-infection. It also manufactures the associated consumables and accessories such as the trophon wall mount, trophon printer, trophon cart, trophon curved probe positioner and others. In addition, the company manufactures and commercializes infection control and decontamination products and services and related technologies. The entity operates in Australia and other countries, of which key revenue is derived from North America.
